Case Report

Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle

Dionysios Dellaportas, James A. Gossage, and Andrew R. Davies

Department of Oesophagogastric Surgery, St Thomas’ Hospital, King’s College London, London, UK

Correspondence should be addressed to Dionysios Dellaportas; dellapdio@gmail.com

Received 12 June 2016; Accepted 3 August 2016

1. Introduction

Improvement of management for cancer patients, increased overall survival, and identification of the disease in early stages have led to the rare event of patients developing a second primary cancer later in their lives. In various studies the incidence of second primary cancer is 6.6–9% [1]. Complex surgery during initial cancer treatment can limit surgical options during management plan of the secondary malignancy. We present an interesting case of a 69-year-old male treated successfully in our institution, who developed gastroesophageal junction adenocarcinoma three years after pancreaticoduodenectomy for pancreatic head adenocarcinoma and finally underwent an extended total gastrectomy. The aim of our study is to highlight the treatment options, the controversies, and the challenging surgical reconstructive options in such a clinical scenario.

2. Case Presentation

A 69-year-old white male patient was investigated for dysphagia and vomiting associated with weight loss. The patient had a medical history of hypertension and hyperlipidemia and a surgical history of pylorus-preserving pancreaticoduodenectomy three years ago for pancreatic head adenocarcinoma. The latter’s histopathological stage was pT1N0 (TNM 7th Edition AJCC classification) and the patient received no adjuvant treatment. Upper gastrointestinal endoscopy revealed an ulcerated, friable tumour of the gastroesophageal junction (GOJ) and histopathology confirmed the presence of poorly differentiated adenocarcinoma. Formal staging of the disease was performed with computed tomography (CT) scan, followed by positron emission tomography (PET/CT) scan and endoscopic ultrasound (EUS) and after multidisciplinary team (MDT) discussion the patient was staged as Siewert
type II cT2N1M0 GOJ adenocarcinoma [2]. No evidence of distant disease from either malignancy was revealed and the patient was considered for radical treatment. According to usual management [3] he received three cycles of neoadjuvant chemotherapy with epirubicin, cisplatin, and capecitabine (ECX protocol), which was well tolerated and with good radiological and clinical response. Restaging CT scan demonstrated regression of the two enlarged left-gastric lymph nodes. The patient was offered either surgery or definite chemoradiotherapy for locoregional control of the disease and chose the former option after extensive counselling as to the associated risks and benefits.

Surgical planning raised some anatomical challenges. Reviewing the pancreaticoduodenectomy reconstruction method from his operative note three years ago, the patient had a pylorus-preserving pancreaticoduodenectomy (PPPD) with an isolated Roux-en-Y reconstruction for the pancreaticojejunostomy. Ligation of the gastroduodenal artery (GDA) was done during PPPD, which gives rise to the right gastroepiploic artery precluding the use of the stomach as conduit for any kind of oesophagogastrectomy. Moreover, the use of colon as a conduit is appealing, but the use of either the left or the right colon involves dissection of the middle colic vessels and meticulous preservation of anastomotic arcades, in an area where the isolated jejunal Roux limb may ascend, retrocolic, and to the left of the above vessels for the pancreaticojejunal anastomosis. Extensive adhesiolysis may be anticipated since the superior mesenteric vessels, which give rise to the middle colic vessels, were dissected during the PPPD.

With all the above in mind, surgical exploration was decided and performed through the old bilateral subcostal incision. The primary tumour involved the GOJ, but after transhiatal mobilization and intraoperative upper gastrointestinal endoscopy it became feasible to get to macroscopically clear margins to the thoracic oesophagus without the need of thoracotomy. In addition, duodenjejunalostomy was antecolic and performed on the long blind ended jejunal loop that originated just below the duodenojejunal flexure from the previous Whipple procedure. After division of the jejunum, an extended total gastrectomy was performed. Oesophagojejunal anastomosis was the only reconstructive anastomosis needed in this complex case to reestablish gastrointestinal continuity. Total operative time was 170 minutes. Final histopathology showed a complete resection (R0) of a ypT1bN0 GOJ poorly differentiated adenocarcinoma, with negative lymph nodes (0/29). The patient had an uneventful postoperative course and was discharged on the 10th postoperative day, while MDT decision was for no adjuvant treatment. He remains well on postoperative surveillance.

3. Discussion

The development of a second malignancy as mentioned above is an unusual event, which is increasingly common in an era of improved survival for cancer patients. Particularly for patients with unfavorable malignancies, like pancreatic, oesophageal, or gastric cancer, the incidence of second primary cancer is less than 5% [1]. Simultaneous or metachronous occurrence of gastroesophageal adenocarcinoma with perianpillary tumours is extremely unusual. In an interesting review of more than 10,000 gastric cancer patients [4], 96 of them had a second primary malignancy and only 5 of them had pancreatic adenocarcinoma. For oesophageal adenocarcinoma patients, the most common second primary malignancies are gastric, oropharyngeal, and lung cancer, while pancreatic cancer is extremely rare [5]. Obviously, common risk factors such as genetic, lifestyle, or dietary factors can give rise to gastrointestinal malignancies of different sites, and if the patient survives long enough after an initial treatment, a second primary gastrointestinal cancer may develop. Surgical resection remains the mainstay of treatment for pancreatic, gastric, and oesophageal cancer.

Technically, surgical strategies have been described in the setting of previous oesophagectomy for the performance of pancreaticoduodenectomy [6], mostly involving the use of colon as conduit, and in the form of case reports. Other challenging options when the right gastroepiploic vessels are compromised include the use of supercharged jejunal interposition conduits [7] or microvascular reconstruction methods for the right gastroepiploic vessels [8, 9]. Oesophagogastrectomy and pancreaticoduodenectomy are individually extensive operations, and their combination either simultaneously or metachronously poses unique challenges. In a recent review of such cases, only three cases involved oesophageal resection after pancreaticoduodenectomy [10]. Our case involved an extended total gastrectomy and intrathoracic oesophagojejunal anastomosis, and to the best of our knowledge it is the first case reporting such a reconstruction configuration.

We suggest careful preoperative planning which includes understanding the method of reconstruction following the previous Whipple procedure and endoscopic assessment of the oesophagogastric primary by the surgical team themselves to establish its exact location. Having at one’s disposal, a variety of surgical strategies for junctional tumours (e.g., extended total gastrectomy, left thoracoabdominal oesophagogastrectomy, substernal colonic interposition, and supercharged jejunal reconstruction methods) afford flexibility that may be crucial in determining success. Furthermore, it is probably unnecessary to dissect all of the jejunum to the pancreas and bile duct in these cases, which may lead to complications. The simplest option remains to use the loop of small bowel previously anastomosed to the stomach/duodenum and (staying close to the bowel wall during its division) mobilize this to reach the oesophagus. Failing this, the jejunum can simply be stapled off and either a Roux loop created distally (beyond the pancreatico- and hepaticojejunoanastomoses) or a colon interposition is used. Postoperatively, nutritional monitoring plays a key role as these patients are at higher risk of the many side effects of complex gastrointestinal surgery such as pancreatic insufficiency, small intestinal bacterial overgrowth, and vitamin/mineral deficiencies.

The use of complex surgery in treatment of cancer patients has made reoperations challenging; however reconstruction options exist and meticulous preoperative planning, imaging tests, and intraoperative judgement help the
surgeon to perform extensive and successful oncologically sound procedures.

**Abbreviations**

GOJ: Gastroesophageal junction
CT: Computed tomography
PET/CT: Positron emission tomography/computed tomography
EUS: Endoscopic ultrasound
MDT: Multidisciplinary team
PPPD: Pylorus-preserving pancreaticoduodenectomy
GDA: Gastroduodenal artery
R0: Complete macroscopic/microscopic resection in clear margins.

**Consent**

A written informed consent has been obtained from the patient.

**Competing Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**References**

[1] R. T. Grundmann and F. Meyer, “Second primary malignancy among cancer survivors—epidemiology, prognosis and clinical relevance,” Zentralblatt für Chirurgie, vol. 137, pp. 565–574, 2012.

[2] J. R. Siewert and H. J. Stein, “Classification of adenocarcinoma of the oesophagogastric junction,” British Journal of Surgery, vol. 85, no. 11, pp. 1457–1459, 1998.

[3] D. Cunningham, W. H. Allum, S. P. Stenning et al., “Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer,” The New England Journal of Medicine, vol. 355, no. 1, pp. II–20, 2006.

[4] T. K. Ha, J. Y. An, H. G. Youn, J. H. Noh, T. S. Sohn, and S. Kim, “Surgical outcome of synchronous second primary cancer in patients with gastric cancer,” Yonsei Medical Journal, vol. 48, no. 6, pp. 981–987, 2007.

[5] N. Nandy and C. A. Dasanu, “Incidence of second primary malignancies in patients with esophageal cancer: a comprehensive review,” Current Medical Research and Opinion, vol. 29, no. 9, pp. 1055–1065, 2013.

[6] D. E. Gyorki, N. E. Clarke, M. W. Hii, S. W. Banting, and R. J. Cade, “Management of synchronous tumours of the oesophagus and pancreatic head: a novel approach,” Annals of the Royal College of Surgeons of England, vol. 93, no. 6, pp. e111–e113, 2011.

[7] Y. Y. Kim, M. M. Hanasono, J. B. Fleming, M. D. Berry, and W. L. Hofstetter, “Combined esophagectomy and pancreaticoduodenectomy: expanded indication for supercharged jejunal interposition,” Journal of Gastrointestinal Surgery, vol. 15, no. 10, pp. 1893–1895, 2011.

[8] A. Inoue, H. Akita, H. Eguchi et al., “ Gastric conduit-preserving, radical pancreaticoduodenectomy with microvascular reconstruction for pancreatic head cancer after esophagectomy: report of a case,” Surgery Today, vol. 44, no. 4, pp. 786–791, 2014.

[9] S. Pagkritis, D. Virvilis, B. T. Phillips et al., “Creation of gastric conduit free-graft with intraoperative perfusion imaging during pancreaticoduodenectomy in a patient post esophagectomy,” International Journal of Surgery Case Reports, vol. 9, pp. 39–43, 2015.

[10] Y. N. Shiryajev, I. Kurosaki, Y. V. Radionov, A. A. Kashintsev, and N. Y. Kokhanenko, “Esophagectomy and pancreaticoduodenectomy in the same patient: tactical and technical considerations,” Hepato-Gastroenterology, vol. 61, no. 133, pp. 1246–1252, 2014.